Fig. 3.

Incidence, severity, and organ class of treatment-emergent adverse events after each dose. Treatment-emergent adverse events after each dose of Nexvax2 or placebo are shown as the number of participants who experienced no, mild, moderate, severe, or serious treatment-emergent adverse events in (A), (C), (E), (G), (I), and (K) and as the total number of treatment-emergent adverse events classified by organ system in (B), (D), (F), (H), (J), and (L). PT, post-treatment.